Related Experiment Video
Updated: Jun 11, 2025
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells
Eman N Ahmed1,2, Lauren C Cutmore1, John F Marshall1
1Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Abstract:
Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of hematological malignancies. Unfortunately, this improvement has yet to be translated into the solid tumor field. Current immunodeficient models used in pre-clinical testing often overestimate the efficacy of CAR T cell therapy as they fail to recapitulate the immunosuppressive tumor microenvironment characteristic of solid tumors. As CAR T cell monotherapy is unlikely to be curative for many solid tumors, combination therapies must be investigated, for example, stromal remodeling agents and immunomodulators. The evaluation of these combination therapies requires a fully immunocompetent mouse model in order to recapitulate the interaction between the host's immune system and the CAR T cells. This review will discuss the need for improved immunocompetent murine models for the pre-clinical evaluation of CAR T cells, the current use of such models and future directions.
Insights
Chimeric antigen receptor (CAR) T cell therapy shows promise for solid tumors but faces challenges. Improved immunocompetent mouse models are crucial for accurately evaluating CAR T cell efficacy and combination therapies in pre-clinical settings.
Area of Science:
- Immunology
- Oncology
- Pre-clinical Research
Background:
- Chimeric antigen receptor (CAR) T cells have transformed hematological cancer treatment.
- CAR T cell therapy efficacy in solid tumors is limited due to the immunosuppressive tumor microenvironment.
- Current immunodeficient models do not accurately reflect solid tumor complexity.
Purpose of the Study:
- To highlight the need for advanced immunocompetent murine models for CAR T cell research.
- To discuss the limitations of current pre-clinical models for solid tumors.
- To explore future directions in developing better models for CAR T cell therapy evaluation.
Main Methods:
- Review of current literature on CAR T cell therapy and pre-clinical models.
- Analysis of the role of the tumor microenvironment in CAR T cell efficacy.
- Discussion of the necessity for immunocompetent models in solid tumor research.
Main Results:
- Immunodeficient models often overestimate CAR T cell efficacy in solid tumors.
- Combination therapies are essential for effective solid tumor treatment.
- Immunocompetent models are required to study host-immune interactions with CAR T cells.
Conclusions:
- Developing and utilizing immunocompetent mouse models is critical for advancing CAR T cell therapy for solid tumors.
- Future research should focus on refining these models to better predict clinical outcomes.
- Accurate pre-clinical evaluation is key to overcoming challenges in solid tumor CAR T cell therapy.
